BioCentury | Apr 13, 2021
Product Development

AACR Quick Takes: Guardant, Gracell, iTeos, Zentalis, ImCheck, PureTech

...I data for iTeos TIGIT mAbiTeos Therapeutics Inc. (NASDAQ:ITOS) reported Phase I data for its anti-TIGIT...
BioCentury | Apr 6, 2021
Management Tracks

Memories of John Martin, plus AACR’s hot targets and a Bio€quity Europe preview: a BioCentury podcast

...conference will showcase the evolution of drug development around two “incredibly important” targets: KRAS and TIGIT...
BioCentury | Apr 3, 2021
Product Development

Digging beyond the headlines at AACR 2021

...Next-wave strategies for KRAS and TIGIT, allogeneic and personalized cell therapies, and targeted protein degraders By...
...BioCentury’s analysis of this year’s AACR meeting unearths orthogonal approaches to high-wattage targets KRAS and TIGIT...
...preclinical data from TIGIT-targeting agents with distinct functional profiles, as well as compounds targeting the TIGIT...
BioCentury | Mar 26, 2021
Product Development

Next-generation checkpoint development surges as rare wins overshadow setbacks

...most notable success was the ASCO readout for anti-TIGIT...
...II study. No Phase III data for TIGIT...
...and two have advanced to Phase III. TIGIT...
BioCentury | Feb 20, 2021
Product Development

BMS turns to mechanistic diversity in early oncology pipeline

...next-generation targets, BMS has a Phase I program against TIGIT...
BioCentury | Feb 2, 2021
Deals

Feb. 1 Quick Takes: Coherus gets rights to Junshi’s PD-1; plus GSK backs newco Adrestia, a seed for Cellino and more

...that includes milestones of up to $1.1 billion, plus royalties. Coherus also receives options to anti-TIGIT...
...be funded through 2023.TARGETSIL-2 – Interleukin 2PD-1 (PDCD1; CD279) – Programmed cell death 1TIGITT cell immunoreceptor with Ig and ITIM domains BC...
BioCentury | Jan 21, 2021
Product Development

Merck KGaA’s bintrafusp alfa miss suggests there’s still more to learn about TGFβ

...other immuno-oncology programs are avelumab and an anti-TIGIT...
...ligand 1TGFβ – Transforming growth factor βTIGITT cell immunoreceptor with Ig and ITIM domains Lauren...
BioCentury | Jan 15, 2021
Product Development

Readout for Arcus’ pancreatic cancer program could spur Gilead to exercise option

...2020 deal that gave the biopharma immediate rights to zimberelimab. Gilead also gained options to Arcus' anti-TIGIT...
...NT5E) - Ecto-5’-nucleotidaseKRAS (K-Ras) - KRAS proto-oncogenePD-1 (PDCD1; CD279) - Programmed cell death 1TIGIT - T cell immunoreceptor with Ig and ITIM domains Paul...
BioCentury | Jan 9, 2021
Finance

Targeted oncology is having a moment, again

...is also paying attention to the evolving TIGIT...
...as strong. Genentech will share biomarker data for anti-TIGIT...
...therapy. Investors are anticipating data from other TIGIT...
BioCentury | Dec 18, 2020
Product Development

Next-generation checkpoints acting on NK and T cells: Data Byte

...By Lauren Martz, Senior Editor Following the early success of anti-TIGIT mAbs in clinical development this...
...CD223) T cell immunoglobulin and mucin domain 3 (TIM3) (HAVCR2) Poliovirus receptor related immunoglobulin domain containing (PVRIG) (CD112R) T cell immunoreceptor with Ig and ITIM domains (TIGIT) CD96...
Items per page:
1 - 10 of 64